MedeAnalytics
PrivateLast Round
Buyout/LBO
Oct 9, 2020
Est. Valuation
$250M
Total Funding Raised
$57M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
MedeAnalytics is a healthcare analytics company that provides an AI-driven, cloud-native, software-as-a-service platform for healthcare organizations to improve financial, operational, and clinical performance.
Sector
Healthcare & Life Sciences
Verticals
Healthcare Analytics, Revenue Cycle, Business Intelligence, Data Integration, Vertical SaaS
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MedeAnalytics Comparables
Compare MedeAnalytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Health Catalyst | 82% | |
| Arcadia | 79% | |
| VisiQuate | 77% |
For institutional investors. Book with your work email.
MedeAnalytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Buyout/LBO | Oct 9, 2020 | ||||
| Buyout/LBO | Sep 30, 2015 | ||||
| Private Equity | Jul 29, 2008 | ||||
| Series A | Apr 1, 2004 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MedeAnalytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Ventures | Buyout/LBO, Private Equity |
| JLL Partners | Buyout/LBO |
| Kennet Partners | Series A |
| Industry Ventures | VC Round, Private Equity |
| Thoma Bravo | Buyout/LBO |
| Emergence Capital | VC Round, Private Equity, Buyout/LBO |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Open roles increased to 424, 126% of current headcount.
- Jul 13, 2026
Open roles increased to 35, 10% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 30, 2026
MedeAnalytics, Inc. introduces Mede Foundation(TM) in Texas on Oct 29th '26 as an ai-native platform that unifies data, intelligence, AI, analytics, and workflow to help health plans make earlier decisions and drive measurable performance.
For institutional investors. Book with your work email.
MedeAnalytics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MedeAnalytics's valuation, stock price, and market status.
Is MedeAnalytics a public or private company?
MedeAnalytics is a private company.
What is the current stock price of MedeAnalytics?
MedeAnalytics is a private company, so its shares have no public market price. Caplight tracks MedeAnalytics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MedeAnalytics worth (valuation)?
MedeAnalytics's valuation is estimated at $250.0M based on funding round data.
Can I buy MedeAnalytics stock?
MedeAnalytics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MedeAnalytics's last funding round?
MedeAnalytics's most recent funding round was Buyout/LBO on October 9, 2020.
Who are the main investors in MedeAnalytics?
Key investors in MedeAnalytics include Bain Capital Ventures, JLL Partners, Kennet Partners, Thoma Bravo.
Will MedeAnalytics IPO soon?
No public IPO plans have been announced for MedeAnalytics.
How can I track MedeAnalytics secondary market activity?
Caplight tracks bids, offers, and trades in MedeAnalytics's shares on secondary markets.